SARS-CoV-2 S2 Monoclonal antibody
To Order Contact us: stephen@expresspharmapulse.com
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
|||
9119-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
|||
9123-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
|||
9123-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
Monoclonal CHP Antibody (monoclonal) (M02), Clone: S2 |
|||
APR15427G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human CHP (monoclonal) (M02). The antibodies are raised in mouse and are from clone S2. This antibody is applicable in WB, E |
Monoclonal KRAS Antibody (monoclonal) (M01), Clone: S2 |
|||
AMM03727G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human KRAS (monoclonal) (M01). The antibodies are raised in Mouse and are from clone S2. This antibody is applicable in WB and IF, E |
Monoclonal UBE2G1 Antibody (monoclonal) (M01), Clone: S2 |
|||
AMM04276G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human UBE2G1 (monoclonal) (M01). The antibodies are raised in mouse and are from clone S2. This antibody is applicable in WB and IF |
Monoclonal ARHGEF5 Antibody (monoclonal) (M01), Clone: S2 |
|||
APR15029G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human ARHGEF5 (monoclonal) (M01). The antibodies are raised in mouse and are from clone S2. This antibody is applicable in WB, E |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [5E6] |
|||
PM-9429-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [5E6] |
|||
PM-9429-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [4F10] |
|||
PM-9428-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [4F10] |
|||
PM-9428-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A6] |
|||
SD9785-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A6] |
|||
SD9785-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1B8] |
|||
SD9787-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1B8] |
|||
SD9787-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1G5] |
|||
SD9789-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1G5] |
|||
SD9789-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A9] |
|||
SD9791-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A9] |
|||
SD9791-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody (biotin) |
|||
9123-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody (biotin) |
|||
9123-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
Monoclonal ACE2 (SARS Receptor) Antibody (Center)(Ascites), Clone: 881CT16.4.4 |
|||
AMM02456G | Leading Biology | 100μl | EUR 580.8 |
Description: A Monoclonal antibody against Human ACE2 (SARS Receptor) (Center)(Ascites). The antibodies are raised in Mouse and are from clone 881CT16.4.4. This antibody is applicable in WB, E |
Phospho-POLR2A (S2) recombinant monoclonal antibody |
|||
A5962 | Bimake | 100ul X 3 | EUR 817.2 |
Description: A recombinant monoclonal antibody from rabbit against human Phospho-POLR2A (S2) for WB,ELISA |
Anti-Phospho-POLR2A (S2) Rabbit Monoclonal Antibody |
|||
P01029-1 | BosterBio | 100ug/vial | EUR 476.4 |
Description: Rabbit Monoclonal Phospho-POLR2A (S2) Antibody. Validated in IP, IF, WB and tested in Human, Mouse, Rat. |
Monoclonal SAR1A Antibody (monoclonal) (M01), Clone: 3G5 |
|||
AMM07710G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human SAR1A (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3G5. This antibody is applicable in WB |
SARS-CoV-2 (COVID-19) S2 Recombinant Protein |
|||
10-426 | ProSci | 0.1 mg | EUR 651.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S2 Recombinant Protein |
|||
11-184 | ProSci | 0.2 mg | EUR 1212 |
Description: It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 Spike S2 Peptide |
|||
9119P | ProSci | 0.05 mg | EUR 235.5 |
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike S2 Peptide |
|||
9123P | ProSci | 0.05 mg | EUR 235.5 |
Description: (CT) SARS-CoV-2 Spike peptide |
Monoclonal SART2 Antibody (monoclonal) (M03), Clone: 6D4 |
|||
AMM04069G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human SART2 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 6D4. This antibody is applicable in WB, E |
MD-2 Monoclonal Antibody |
|||
26026-100ul | SAB | 100ul | EUR 468 |
MD-2 Monoclonal Antibody |
|||
26027-100ul | SAB | 100ul | EUR 468 |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
9155-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
9155-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
9159-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
9159-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
|||
9161-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
|||
9161-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |